YS Biopharma Co., Ltd. reported on February 22, 2024, an update regarding beneficial ownership, indicating 95.3 million shares were sold previously and revealing ownership distribution among executives and major shareholders. The primary owner is Apex Prospect Limited with 52.2% of shares, and Yi Zhang holds 26.1%.